Low-density lipoprotein receptor-related protein-1 (LRP) on brain capillaries clears amyloid b-peptide (Ab) from brain. Here, we show that soluble circulating LRP (sLRP) provides key endogenous peripheral 'sink' activity for Ab in humans. Recombinant LRP cluster IV (LRP-IV) bound Ab in plasma in mice and Alzheimer's disease-affected humans with compromised sLRP-mediated Ab binding, and reduced Ab-related pathology and dysfunction in a mouse model of Alzheimer disease, suggesting that LRP-IV can effectively replace native sLRP and clear Ab.
Two major binding domains of LRP, cluster II and cluster IV 8 , bind Ab in vitro with high affinity: i.e., Ab40 4 Ab42 (ref. 2) . We hypothesized that LRP recombinant cluster IV (LRP-IV) retains its high-affinity binding for Ab in vivo, and that this binding alters Ab transport at the BBB, which is dominated by the cell-surface LRP [1] [2] [3] [4] and the receptor for advanced glycation end-products (RAGE) 9 , resulting in Ab efflux from the brain. We also hypothesized that plasma sLRP binds Ab in vivo, which regulates Ab metabolism and clearance under physiological conditions and in Alzheimer's disease.
We found that the relative in vitro ligand-binding affinities for LRP-IV were, in descending order (referring in all cases to the human proteins), Ab40 4 Ab42 c apolipoprotein E3 (apoE3) 4 apoE4 c tissue plasminogen activator (tPA), as indicated by their respective binding constants, K d , of 1.9, 5.1, 22.3, 29.9 and 172 nM (Supplementary Fig. 1a -c,e online). K d values for mouse apoE and tPA were 16.9 and 21.2 nM, respectively ( Supplementary Fig. 1d,e) . Thus, LRP-IV preferentially bound Ab peptides as compared to other LRP ligands.
By using an in situ arterial brain perfusion technique in mice 9 , we showed that LRP-IV completely blocked transport of circulating 125 I-Ab40 across the BBB, and itself was not transported across the BBB ( Supplementary Fig. 2a-c online) . As determined from the 24-h plasma profile of intact 125 I-LRP-IV after an intravenous injection ( Supplementary Fig. 2d ), the half-time of LRP-IV elimination, e t1/2 , was 11.8 h, and the mean residence time of LRP-IV in the circulation was 14 h. We also found that 125 I-LRP-IV and/or 125 I-LRP-IV-Ab complexes were removed by liver, kidney and spleen, but were not taken up by brain within 24 h ( Supplementary Fig. 2e ,f). LRP-IV --+ P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.01 P < 0.02 P < 0.03 Short-term LRP-IV treatment reduced mouse endogenous brain Ab40 and Ab42 by 51% and 27%, respectively (Fig. 1a) , and increased plasma Ab40 and Ab42 (Fig. 1b) . After LRP-IV treatment, plasma Ab40 and Ab42 were associated mainly with LRP-IV, as shown by analysis of Ab in pellets of sLRP-depleted plasmas precipitated with receptor-associated protein 10, 11 ( Supplementary Fig. 3a-d , Supplementary Methods online). These results were consistent with the 4-5-fold lower affinity of Ab for mouse endogenous sLRP (Supplementary Fig. 3e ) as compared to LRP-IV ( Supplementary Fig. 1a) . We did not detect either sLRP or LRP-IV in the cerebrospinal fluid (CSF) ( Supplementary Fig. 4a online) .
Chronic treatment of mice heterozygous for the sw mutation of APP, the gene encoding Ab precursor protein (APP +/sw , also called APPsw +/-, mice), with low-dose LRP-IV beginning at 6 months of age increased cerebral blood flow responses to whisker stimulation by 65% (Fig. 1c) and improved operant learning (Fig. 1d) and spatial (Fig. 1e) and recognition (Fig. 1f ) memory almost to their levels in nontransgenic controls. We did not find differences in behavior in wild-type mice after LRP-IV or vehicle treatment (data not shown).
In LRP-IV-treated as compared to vehicle-treated APP +/sw mice, Ab40 and Ab42 levels in hippocampus and cortex were reduced by 72% and 61% and by 480% and 90%, respectively (Fig. 1g,h ). LRP-IV substantially reduced total Ab load (Fig. 2a) , amyloid vascular and parenchymal load (Fig. 2b) and Ab parenchymal and vascular load ( Supplementary Fig. 5a-e online) . The ability of LRP-IV to remove vascular Ab and vascular amyloid is critical, because in mouse models of Alzheimer's disease, dense plaques develop initially on blood vessels 2, 12 .
LRP-IV increased plasma Ab40 and Ab42 in APP +/sw mice (Fig. 2c) , sequestered 52-55% of total Ab and reduced free Ab42 and Ab40 ( Supplementary Fig. 3f,g ). We did not find LRP-IV or sLRP in the CSF of APP +/sw mice ( Supplementary Fig. 4b ).
LRP-IV moderately reduced plasma cholesterol in APP +/sw mice, but did not alter plasma levels of major LRP ligands, such as apoE, tPA or pro-matrix metalloproteinase-9 ( Supplementary Fig. 6a-d  online) . After LRP-IV treatment, we did not find changes in the expression of lipoprotein receptors in brain, kidney or liver (Supplementary Fig. 6e-h) .
To test whether Ab-lowering effect of LRP-IV remains when treatment is initiated at a time point when APP +/sw mice develop prominent cerebral amyloid angiopathy and parenchymal plaques 13,14 , we treated 11-month-old APP +/sw mice for 6 weeks with LRP-IV or vehicle. Again, LRP-IV reduced Ab pathology and vascular and brain amyloid deposition by 490% ( Supplementary Fig. 7 online) without causing microhemorrhages, as demonstrated by negative Prussian blue staining (data not shown).
In individuals with Alzheimer's disease, sLRP plasma levels were 30% lower than in non-demented controls (Fig. 2d) . There was a 280% increase in oxidized sLRP (Fig. 2e) , which showed extremely low affinity for Ab42 and Ab40 ( Supplementary  Fig. 3h ). The cohort of individuals with Alzheimer's disease we studied did not show evidence of polymorphism in the LRP gene (Supplementary Table 1 online) .
We next showed that native sLRP is a major binding protein for Ab in human plasma (Fig. 2f-g ). After coimmunoprecipitation of sLRP-bound Ab, we found that about 70% of Ab40 and about 90% of Ab42 were normally bound to plasma sLRP in controls. In individuals with Alzheimer's disease, there was a 30-35% drop in sLRP-bound Ab40 and Ab42 associated with a 300-400% increase in free, protein-unbound Ab40 and Ab42 (Fig. 2f,g) . A minor fraction of Ab (430 kDa) was associated with non-sLRP carriers, such as apoJ (data not shown), in both controls and affected individuals. Incubation of plasma from individuals with Alzheimer's disease with low-dose LRP-IV eliminated free Ab40 and Ab42 and significantly decreased (P o 0.05) sLRP-bound Ab42 and Ab40 (Fig. 2h) .
Our data suggest that recombinant LRP-IV does not penetrate the BBB and CSF and lowers brain Ab through peripheral binding with no direct central actions. Compared to non-immune Ab-binding agents, LRP-IV was effective at substantially lower levels. For example, in transgenic mice overexpressing a mutant form of human APP encoded by a minigene with several substitutions found in familial Alzheimer's disease (V717F, K670M and N671L) under the control of the PDGF b-chain promoter (PD-hAPP), soluble RAGE exerted an Ab-lowering effect at a daily molar dose B50-fold greater 9 than LRP-IV. Gelsolin and ganglioside M1 lowered brain Ab in transgenic mice overexpressing a mutant form of human presenilin-1 gene (M146L) and APP +/sw (PS1/APP +/sw mice) 15 at a molar daily dose an order of magnitude greater than LRP-IV.
We have demonstrated that native sLRP normally controls 70-90% of circulating Ab in humans through peripheral binding. This sLRP function is compromised in Alzheimer's disease, which may contribute to elevated brain Ab. LRP-IV effectively sequestered Ab in Alzheimer's disease-derived plasma and in APP +/sw mice, in the latter case resulting in Ab efflux from mouse brain. Thus, LRP-IV could serve as a Ab clearance and sLRP replacement therapy for Alzheimer's disease, with an enhanced peripheral 'sink' activity for Ab as compared to endogenous sLRP.
